@article{c5ac4a753c2b4f03bbf6551a82a8dccd,
title = "Has dose-dense chemotherapy met an ICONic end?",
author = "Hinchcliff, {Emily M.} and Meyer, {Larissa A.} and Westin, {Shannon N.}",
note = "Funding Information: EMH reports no competing interests. LAM reports research funding from AstraZeneca. SNW reports personal fees for consulting from AstraZeneca, Circulogene, Clovis Oncology, Merck, Novartis, Pfizer, Roche/Genentech, GSK/Tesaro, and Eisai and research funding to her institution from ArQule, AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, Novartis, Roche/Genentech, and GSK/Tesaro. EMH is supported by a National Institutes of Health (NIH) T32 grant (CA101642). LAM is supported by a NIH K07 grant (CA201013). SNW is supported by NIH SPORE in Ovarian Cancer (1P50CA217685-01) and a Gynecologic Oncology Group Foundation Scholar Investigator Award. Funding Information: EMH reports no competing interests. LAM reports research funding from AstraZeneca. SNW reports personal fees for consulting from AstraZeneca, Circulogene, Clovis Oncology, Merck, Novartis, Pfizer, Roche/Genentech, GSK/Tesaro, and Eisai and research funding to her institution from ArQule, AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, Novartis, Roche/Genentech, and GSK/Tesaro. EMH is supported by a National Institutes of Health (NIH) T32 grant ( CA101642 ). LAM is supported by a NIH K07 grant ( CA201013 ). SNW is supported by NIH SPORE in Ovarian Cancer ( 1P50CA217685-01 ) and a Gynecologic Oncology Group Foundation Scholar Investigator Award.",
year = "2020",
month = jul,
doi = "10.1016/S1470-2045(20)30276-X",
language = "English (US)",
volume = "21",
pages = "869--870",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "7",
}